Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Levacetylleucine

10 evidence topics · 11 sources

Open-label extension at 12 and 18 months compared with a historical cohort

“Fifty-three patients aged 5–67 years (45.3% female, 54.7% male) were enrolled in the EP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean (±SD) baseline (visit 2) score on the 5-domain NPC-CSS was 11.10 (±4.73).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After 12 months, the mean (±SD) change from baseline on the 5-domain NPC-CSS was −0.27 (±2.42) with NALL vs +1.5 (±3.16) in the historical cohort (95% CI −3.05 to −0.48; p = 0.009), corresponding to a 118% reduction in annual disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After 18 months, the mean (±SD) change was +0.05 (±2.95) with NALL vs +2.25 (±4.74) in the historical cohort (95% CI −4.06 to −0.35; p = 0.023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Subgroup analysis of pediatric vs adult patients demonstrated consistent benefit with NALL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No TEAEs occurred in more than 10% of patients on NALL, and no patients had TEAEs that were assessed by the investigator as related to NALL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote